MicroRNA and Cardiovascular Diseases
İçerik yapay zeka ile optimize edilmiştir
Cardiovascular Diseases and the Need for Novel Biomarkers
Cardiovascular diseases (CVDs) remain one of the primary causes of mortality globally, affecting both developing and developed nations. Despite significant advancements in primary prevention strategies, the prevalence of these conditions has continued to rise in recent years. This trend underscores the critical importance of investigating the molecular pathophysiology of CVDs in-depth to improve clinical outcomes.
To enhance early prevention and accurate diagnosis, identifying novel biomarkers is essential. Current research focuses on understanding the underlying mechanisms of these diseases to develop more effective diagnostic tools. Among the most promising candidates in this field are microRNAs (miRNAs), which offer significant potential for clinical application.
Understanding MicroRNAs: Structure and Biological Roles
MicroRNAs (miRNAs) are endogenous, conserved, single-stranded non-coding RNAs typically consisting of 21-25 nucleotides. These molecules play fundamental roles in various cellular processes, ensuring the proper functioning of biological systems. Their influence spans across several critical areas, including:
- Embryogenesis and cell growth
- Cellular proliferation and differentiation
- Vasculogenesis and apoptosis
- Tumorigenesis
In the context of the cardiovascular system, miRNAs are involved in angiogenesis, cardiac cell contractility, and the regulation of lipid metabolism. Furthermore, they contribute to plaque formation, the arrangement of cardiac rhythm, and the control of cardiac cell growth.
miRNAs as Diagnostic and Prognostic Tools
Circulating miRNAs are emerging as highly effective biomarkers for the diagnosis and prognosis of cardiovascular diseases. Their unique biological properties make them superior to many traditional markers. The potential of miRNAs as surrogate markers is supported by several key factors:
| Feature | Clinical Advantage |
|---|---|
| Stability | Highly stable in serum and plasma environments. |
| Resistance | Resistant to degradative factors like freeze-thaw cycles and blood enzymes. |
| Kinetics | Exhibit fast-release kinetics for timely detection. |
| Specificity | Demonstrate high cell or tissue specificity. |
These characteristics allow for the early and accurate diagnosis of diseases and the prediction of middle- or long-term prognosis. Integrating miRNAs with traditional biomarkers may also provide a more logical approach to improving risk stratification.
Therapeutic Applications of miRNA-Based Platforms
Beyond their diagnostic utility, miRNA-based therapeutics represent a novel frontier in treating cardiovascular diseases. These therapeutic agents can influence multiple genes simultaneously through various signaling pathways. By utilizing advanced computational tools and novel platforms, miRNA modulation can be combined with traditional analytical methods for enhanced efficacy.
Clinical Settings for miRNA Modulation
Therapeutic modulation techniques involving miRNAs have been explored across a wide range of cardiovascular conditions, including:
- Atherosclerosis and acute myocardial infarction.
- Restenosis and vascular remodeling.
- Arrhythmias, hypertrophy, and fibrosis.
- Angiogenesis, cardiogenesis, and aortic aneurysm.
- Pulmonary hypertension and ischemic injury.
This review provides a comprehensive overview of miRNA structure, biogenesis, and synthesis stages. It further details their expression profiles in living organisms and evaluates their transformative potential as novel therapeutic agents and diagnostic tools in modern medicine.
